Clinical trials: Atopic Dermatosis
Atopic Dermatitis
A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.
- Trial name
- NCT07106372
- Testing
- Stapokibatrt
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Keymed Biosciences Co.Ltd
Asthma, COPD
An Evaluation of 9MW1911 Injection in Healthy Subjects
This study is a randomized, double-blind, dose-escalating phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of 9MW1911 injection in healthy subjects.
- Conditions
- Asthma, COPD, Atopic Dermatitis
- Trial name
- NCT05803902
- Testing
- Experimental drug 9MW1911
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Atopic Dermatitis
A Study of TAVO101 in Atopic Dermatitis Patients
This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.
- Trial name
- NCT06176040
- Testing
- TAVO101
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Tavotek Biotherapeutics
Atopic Dermatitis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic Dermatitis
- Trial name
- NCT02932891
- Testing
- DSXS topical
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis
A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.
The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical…
- Trial name
- NCT05387980
- Testing
- CIBINQO
- Where
- Japan
- Volunteers
- 1,128 people
- Sponsor
- Pfizer
Atopic Dermatitis
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
RBN-3143 Background: PARP proteins are members of a family of seventeen ADP-ribosyltransferase (ART) enzymes that regulate cellular processes including gene expression, protein degradation, and multiple cellular stress responses.
- Trial name
- NCT05215808
- Testing
- RBN-3143
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ribon Therapeutics, Inc.
Atopic Dermatitis, Asthma
A Clinical Study to Evaluate SM17 in Healthy Participants
This is a phase I study in Chinese healthy adult volunteer participants. It aims to evaluate the safety, tolerability, PK profile and immunogenicity of a single dose of SM17 SC in healthy Chinese adult participants.
- Conditions
- Atopic Dermatitis, Asthma, Inflammatory Bowel Disease
- Trial name
- NCT07466940
- Testing
- SM17
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SinoMab BioScience Ltd
Dermatitis
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
- Trial name
- NCT01259323
- Testing
- REGN668
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
The purpose of this randomized, double-blind, placebo-controlled, sequential-cohort, dose-escalation study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of S-777469, a CB2 cannabinoid receptor…
- Trial name
- NCT00697710
- Testing
- 50 mg S-777469, 200 mg S-777469, 800 mg S-777469
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Shionogi
Healthy, Chronic Rhinosinusitis With Nasal Polyps
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with…
- Conditions
- Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
- Trial name
- NCT02743871
- Testing
- PF-06817024
- Where
- 20 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at…
- Trial name
- ROCKET-SHUTTLE (NCT05724199)
- Testing
- Rocatinlimab
- Where
- 234 sites in United States, Argentina and 24 more
- Volunteers
- 746 people
- Sponsor
- Amgen
Atopic Dermatitis
Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis
This was a multi-center, randomized, double-blind, parallel group study. Efficacy Objectives: To evaluate the efficacy of CD2027 ointment 3 mcg/g applied twice daily over 4 weeks versus its vehicle in adult participants with at…
- Trial name
- NCT00919763
- Testing
- CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
- Where
- 14 sites in United States
- Volunteers
- 102 people
- Sponsor
- Galderma R&D
Dermatitis, Atopic
Pharmacokinetic Study of Topical GSK2894512 Cream
This study will assess the systemic exposure and pharmacokinetic parameters of GSK2894512 following twice daily topical administration of 1% and 2% cream in adult subjects with AD, and will provide information about the systemic…
- Trial name
- NCT02466152
- Testing
- GSK2894512 Topical Cream
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks
Pierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment of eczemas, including atopic eczema, contact eczema and chronic hand eczema.
- Trial name
- NCT07014007
- Testing
- RV4421B- EV0407
- Where
- Mauritius
- Volunteers
- 105 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease…
- Trial name
- PROADAP (NCT06415175)
- Testing
- Dupilumab
- Where
- 15 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.
- Trial name
- NCT05375929
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Pfizer
Dermatitis, Atopic
WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients
Study to investigate the safety and efficacy of WAL 801 CL Dry Syrup on pruritus associated with paediatric atopic dermatitis in comparison with that of Ketotifen Fumarate Dry Syrup and to confirm the appropriateness of dosage of…
- Trial name
- NCT02182557
- Testing
- WAL 801 CL Dry Syrup, Ketotifen Fumarate Dry Syrup
- Volunteers
- 162 people
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
- Trial name
- NCT03100344
- Testing
- Nemolizumab
- Where
- 67 sites in United States, Australia and 4 more
- Volunteers
- 226 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT05240300
- Testing
- BX005-A
- Sponsor
- BiomX, Inc.
Atopic Dermatitis
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
It is a randomized, double-blinded, parallel, single-dose, PhaseⅠcomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent® in healthy Chinese adult subjects.
- Trial name
- NCT06614907
- Testing
- QL2108 injection, Dupixent®
- Where
- China
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.